RE:RE:RE:XB3 and its cost in the health care system?It was a good question, narmac. In earlier days Bioasis was dealing with chemical conjugates like BT2111 that was so successfully tested at Texas Tech. BT2111 was a combination of melanotransferrin (p97) and trastuzumab (with a linker between them, I believe).
The conjugation was done by physically mixing the two with a linker in a container of some sort. Several chemical reactions and combinations were possible. It's been a while but I recollect that separating the structure you want from the resulting mixture would be very expensive in a manufacturing process, with the quality control required by the FDA being very difficult and expensive to achieve.
Using fusion proteins is cheaper and has many advantages that chemical conjugates are seriously lacking.
jd